Market Insider

Stocks to Watch: RIMM, NKE, F, GS & More


Take a look at some of Friday's morning movers:

Research In Motion - The company posted a quarterly loss of $0.37 per share, much wider than consensus estimates of a $0.03 per share loss. Revenue also came in light, with the BlackBerry maker saying the next several quarters would be “very challenging.” The company is also pushing back the launch of its new BlackBerry 10 operating system to early 2013.

Nike - The athletic footwear and apparel maker is reporting of $1.17 per share, 20 cents below estimates, with revenues also falling short of consensus. Higher raw material costs are among the factors cited, as Nike misses Street estimates for the first time in two years.

Ford Motor - The automaker says its international losses will triple during the second quarter, largely because of weaker European sales.

Goldman Sachs - The firm is cutting from its U.S. operations, as it seeks to cut costs because of slowing capital market activity.

ServiceNow - ServiceNow has priced its initial public offering at $18, with the provider of cloud-based services for business set to begin trading on the New York Stock Exchange this morning.

  • Key Health-Care Stocks Following Supreme Court Ruling

Anheuser-Busch InBev - The beer brewer has completed the purchase of the half of that it didn’t already own for $20.1 billion. In a related deal, Constellation Brands bought the 50 percent of Crown Imports that it didn’t already own from AB InBev. Crown had been a joint venture between Constellation and Modelo.

Royal Bank of Scotland - The bank will reportedly be fined $233 million in connection with the same that saw Barclays Thursday. That’s according to the Times of London.

Finish Line - The athletic apparel maker earned $0.24 a year for the first quarter, one cent above estimates. Revenue was essentially in line with consensus.

Saks - The retailer's shares were upgraded to "overweight" from "neutral" at JPMorgan Chase, with the price target increased to $12 from $11.

Human Genome Sciences - RBC Capital analyst Michael Yee says the drugmaker could draw a bid worth $15 per share, two dollars higher than the current bid on the table from GlaxoSmithKline.

Oracle - The stock has been upgraded to "outperform" from "sector perform" at RBC Capital, with the firm citing an accelerated growth outlook for the enterprise software maker.

—By CNBC’s Peter Schacknow

Questions? Comments? Email us at